GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soleno Therapeutics Inc (NAS:SLNO) » Definitions » Shiller PE Ratio

Soleno Therapeutics (Soleno Therapeutics) Shiller PE Ratio : (As of Jun. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Soleno Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Soleno Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Soleno Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soleno Therapeutics Shiller PE Ratio Chart

Soleno Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Soleno Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Soleno Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Soleno Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soleno Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soleno Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Soleno Therapeutics's Shiller PE Ratio falls into.



Soleno Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Soleno Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Soleno Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.59/131.7762*131.7762
=-0.590

Current CPI (Mar. 2024) = 131.7762.

Soleno Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -149.510 100.560 -195.922
201409 -27.728 100.428 -36.383
201412 -79.981 99.070 -106.386
201503 -125.250 99.621 -165.677
201506 18.750 100.684 24.540
201509 -24.750 100.392 -32.487
201512 -6.750 99.792 -8.913
201603 -16.500 100.470 -21.641
201606 -17.250 101.688 -22.354
201609 -13.050 101.861 -16.883
201612 -29.850 101.863 -38.616
201703 -8.550 102.862 -10.953
201706 -6.300 103.349 -8.033
201709 -5.850 104.136 -7.403
201712 -6.000 104.011 -7.602
201803 -2.850 105.290 -3.567
201806 -5.250 106.317 -6.507
201809 -1.950 106.507 -2.413
201812 0.150 105.998 0.186
201903 -3.300 107.251 -4.055
201906 -4.650 108.070 -5.670
201909 -2.850 108.329 -3.467
201912 -5.400 108.420 -6.563
202003 -1.950 108.902 -2.360
202006 -2.400 108.767 -2.908
202009 -1.650 109.815 -1.980
202012 -0.600 109.897 -0.719
202103 -1.650 111.754 -1.946
202106 -2.100 114.631 -2.414
202109 -1.530 115.734 -1.742
202112 -0.530 117.630 -0.594
202203 -1.070 121.301 -1.162
202206 -0.720 125.017 -0.759
202209 -0.650 125.227 -0.684
202212 -0.580 125.222 -0.610
202303 -0.880 127.348 -0.911
202306 -0.810 128.729 -0.829
202309 -0.950 129.860 -0.964
202312 -0.357 129.419 -0.364
202403 -0.590 131.776 -0.590

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Soleno Therapeutics  (NAS:SLNO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Soleno Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Soleno Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Soleno Therapeutics (Soleno Therapeutics) Business Description

Traded in Other Exchanges
Address
203 Redwood Shores Parkway, Suite 500, Redwood City, CA, USA, 94065
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome.
Executives
Patricia C Hirano officer: See Remarks 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Kristen Yen officer: See Remarks 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
Bhatnagar Anish director, officer: See Remarks 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
James H Mackaness officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Abingworth Bioventures Vii Lp 10 percent owner PRINCES HOUSE, 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew Pauls director 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Carlyle Holdings I L.p. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Sub L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505